Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate safety, tolerability and pharmacokinetics of the liver-selective TR-beta agonist VK2809 (MB07811) in hypercholesterolemic subjects.

Trial Profile

A phase 1b randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate safety, tolerability and pharmacokinetics of the liver-selective TR-beta agonist VK2809 (MB07811) in hypercholesterolemic subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VK 2809 (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Metabasis Therapeutics
  • Most Recent Events

    • 16 Nov 2016 Results of effect of VK-2809 on lipoprotein-A and Apolipoprotein B presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 15 Nov 2016 According to Viking Therapeutics Media Release, results were presented in a poster presentation at the American Heart Association (AHA) Scientific Sessions 2016.
    • 15 Nov 2016 Results published in the Viking Therapeutics Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top